Abstract
Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.
Conclusion: This review focuses on current evidence available for various antiplatelet regimens and statin therapy for PAD and discusses future perspectives. We consider randomized controlled trials, together with the most important reviews and meta-analyses. Treatment algorithms based on currently available data.Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.
Current Vascular Pharmacology
Title:Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Volume: 15 Issue: 5
Author(s): Panagiotis Kitrou, Konstantinos Katsanos, Dimitris Karnabatidis, Lazaros Reppas, Elias Brountzos and Stavros Spiliopoulos*
Affiliation:
- Attiko University Hospital, 2nd Radiology Department, Division of Interventional Radiology, GR 12461, 1st Rimini St, Chaidari, Athens,Greece
Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.
Abstract: Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.
Conclusion: This review focuses on current evidence available for various antiplatelet regimens and statin therapy for PAD and discusses future perspectives. We consider randomized controlled trials, together with the most important reviews and meta-analyses. Treatment algorithms based on currently available data.Export Options
About this article
Cite this article as:
Kitrou Panagiotis , Katsanos Konstantinos , Karnabatidis Dimitris , Reppas Lazaros, Brountzos Elias and Spiliopoulos Stavros*, Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease, Current Vascular Pharmacology 2017; 15 (5) . https://dx.doi.org/10.2174/1570161115666170504124911
DOI https://dx.doi.org/10.2174/1570161115666170504124911 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Gene Patents Related to Common Diseases of the Eye
Recent Patents on DNA & Gene Sequences 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology Chemoprevention Strategies for High Risk Women
Current Women`s Health Reviews Improving RBC K Transport and Hemoglobin-O2 Binding by Amiloride: A Novel Therapeutic Approach for Reversion of Angina and Myocardial Ischemia in Coronary Heart Diseases
Recent Patents on Cardiovascular Drug Discovery Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology